Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PBZ vs ACUVUE THERAVISION WITH KETOTIFEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
PBZ (phenylbutazone) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis. It also has uricosuric effects.
Ketotifen is a selective histamine H1-receptor antagonist and mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and leukotrienes from mast cells.
FDA-approved for relief of acute gouty arthritis and ankylosing spondylitis,Off-label for rheumatoid arthritis and other inflammatory conditions (rarely used due to toxicity)
FDA-approved for the prevention and treatment of ocular itching associated with allergic conjunctivitis
25-50 mg orally every 4-6 hours as needed; not to exceed 300 mg/day. For severe allergies: 25 mg intramuscularly or intravenously every 4-6 hours.
One drop in each affected eye twice daily (approximately 8 hours apart) as needed. The lens should be removed prior to instillation and can be reinserted after at least 10 minutes.
Terminal elimination half-life: 8-12 hours in adults; prolonged in renal impairment (up to 24 hours).
12 hours (terminal elimination half-life; clinical context: twice-daily dosing needed for continuous effect).
Primarily hepatic via CYP450 enzymes (including CYP2C9), with renal excretion of metabolites.
Not significantly metabolized in the eye; systemic absorption is minimal. After systemic absorption, it is metabolized primarily via glucuronidation and oxidation, with a half-life of approximately 12 hours.
Renal excretion of unchanged drug (approximately 70-80%) with the remainder as metabolites. Biliary/fecal excretion accounts for <5%.
Renal (approximately 50% as unchanged drug, 30% as metabolites); biliary/fecal elimination accounts for <10%.
95-98% bound to albumin and alpha-1-acid glycoprotein.
99% (primarily albumin and alpha-1-acid glycoprotein).
2-3 L/kg, indicating extensive tissue distribution.
2.4 L/kg (high tissue distribution, including ocular tissues).
Oral: 60-70% (first-pass metabolism reduces absolute bioavailability).
Ocular topical: ~0.1% systemic; oral: 70% (not relevant for contact lens application).
No specific guidelines available; use with caution in severe renal impairment (GFR <10 m L/min) due to potential accumulation. Consider dose reduction or increased dosing interval.
No dosage adjustment required based on renal function; systemic absorption is minimal.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50% and monitor for sedation; Child-Pugh Class C: avoid use due to risk of hepatic encephalopathy or reduce dose by 75%.
No dosage adjustment required based on hepatic function; systemic absorption is minimal.
Children 2-6 years: 5 mg orally every 4-6 hours, not to exceed 30 mg/day; Children 6-12 years: 10-15 mg orally every 4-6 hours, not to exceed 60 mg/day; Children >12 years: adult dose.
Safety and efficacy in pediatric patients below 3 years of age have not been established. For children 3 years and older, administer one drop in each affected eye twice daily.
Start at 10 mg orally every 6-8 hours; titrate cautiously due to increased sensitivity (sedation, dizziness, anticholinergic effects). Avoid if possible; consider alternative antihistamine with lower anticholinergic burden.
No specific dosage adjustment is required for elderly patients; use same dosing as for adults.
Risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation; risk of cardiovascular thrombotic events; use is contraindicated for perioperative pain in CABG surgery.
None
Risk of agranulocytosis, aplastic anemia, and other blood dyscrasias; GI toxicity; cardiovascular events; renal toxicity; hepatic effects; use only when other NSAIDs are ineffective and for short durations; contraindicated in patients with aspirin-sensitive asthma.
For topical ophthalmic use only; not for injection.,Contains benzalkonium chloride; soft contact lens wearers should remove lenses before application and wait at least 10 minutes before reinserting.,May cause transient stinging or burning upon instillation.,Use with caution in patients with known hypersensitivity to any component.
History of hypersensitivity to NSAIDs; active GI bleeding or peptic ulcer disease; severe hepatic or renal impairment; known coronary artery bypass graft (CABG) surgery; blood dyscrasias.
Hypersensitivity to ketotifen or any component of the product.
Avoid concurrent use of alcohol and other CNS depressants. No specific food restrictions, but grapefruit juice has not been studied with this drug. Administer with food if gastrointestinal discomfort occurs.
None reported.
PBZ (Piroxicam) is a nonsteroidal anti-inflammatory drug (NSAID). First trimester: Avoid use; associated with increased risk of miscarriage and congenital malformations (e.g., cardiac defects) due to prostaglandin synthesis inhibition. Second trimester: Use only if clearly needed; potential for oligohydramnios and fetal renal dysfunction. Third trimester: Contraindicated; risk of premature closure of ductus arteriosus, persistent pulmonary hypertension, and oligohydramnios.
Ketotifen ophthalmic solution has minimal systemic absorption (approximately 0.1% of administered dose). No adequate well-controlled studies in pregnant women. Animal studies showed no teratogenicity at doses up to 50 mg/kg/day orally. Risk to fetus is considered low when used topically as directed.
PBZ is excreted into breast milk in low concentrations. The milk-to-plasma ratio is approximately 0.01-0.2. Due to potential adverse effects on infant cardiovascular and renal systems (e.g., platelet dysfunction, renal impairment), use is generally not recommended. Consider alternative analgesics with more established safety profiles.
Ketotifen is excreted in human milk following oral administration; however, systemic absorption from ophthalmic use is negligible. M/P ratio not established for ophthalmic route. Consider benefit vs risk; caution in breastfeeding mothers.
Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered clearance) may require dose adjustments. However, due to teratogenic risks, PBZ is generally avoided during pregnancy. If use is unavoidable, use the lowest effective dose for the shortest duration, with careful monitoring.
No dosage adjustment required. Use as directed; pharmacokinetic changes in pregnancy are not significant for topical ophthalmic route.
PBZ (tripelennamine) is a first-generation antihistamine with sedative properties. It is used primarily for allergic conditions and pruritus. Avoid in patients with narrow-angle glaucoma, prostatic hyperplasia, or urinary retention. Monitor for anticholinergic effects (dry mouth, blurred vision, constipation). May cause paradoxical excitation in children. Dose reduction needed in hepatic impairment.
Ketotifen is a mast cell stabilizer and antihistamine; contact lens must be removed before instillation and may be reinserted after 10 minutes. Do not use while wearing contact lenses. Advise patient to wait at least 5 minutes between different eye drops. The preservative benzalkonium chloride may be absorbed by soft contact lenses.
Do not drive or operate heavy machinery until you know how this medication affects you, as it may cause drowsiness.,Avoid alcohol and other CNS depressants to prevent increased sedation.,Take with food or milk to reduce stomach upset.,Do not crush or chew extended-release tablets; swallow whole.,Contact your doctor if you experience blurred vision, difficulty urinating, or severe constipation.,May cause dry mouth; use sugar-free gum or candy to alleviate.,Store at room temperature away from moisture and heat.,Keep out of reach of children; overdose may cause hallucinations or seizures.
Remove contact lenses before using the drops and wait at least 10 minutes before reinserting.,Wash hands before use. Do not touch the dropper tip to any surface, including the eye.,Do not use if the solution changes color or becomes cloudy.,Use exactly as prescribed; do not use more often than directed.,If you miss a dose, use it as soon as possible. If it is almost time for the next dose, skip the missed dose and resume your regular schedule. Do not double the dose.,Contact your doctor if you experience eye pain, vision changes, or if symptoms persist or worsen.
No interactions on record
"Lisdexamfetamine, a prodrug of dextroamphetamine, increases central nervous system (CNS) arousal via dopamine and norepinephrine release, counteracting the sedative effects of ketotifen, a mast cell stabilizer with histamine H1-receptor antagonism and CNS depressant properties. The interaction results in reduced sedative efficacy of ketotifen, potentially affecting therapeutic outcomes in allergic conditions where sedation is beneficial, such as severe pruritus or urticaria. Clinically, patients may experience decreased drowsiness or sleepiness, which could be undesirable if ketotifen is prescribed specifically for its soporific effects."
"Pseudoephedrine, a sympathomimetic amine, exerts central nervous system (CNS) stimulant effects by indirectly activating adrenergic receptors, which can counteract the sedative properties of ketotifen, a histamine H1-receptor antagonist with mast cell stabilizing activity. This pharmacodynamic antagonism may reduce the therapeutic efficacy of ketotifen in managing allergic conditions, particularly its ability to cause drowsiness as a side effect. Clinically, patients may experience diminished sedation, potentially leading to decreased compliance or altered therapeutic outcomes in conditions where sedation is beneficial."
"Hydroxyamphetamine, an indirect-acting sympathomimetic amine, stimulates the release of norepinephrine from presynaptic nerve terminals, leading to activation of alpha- and beta-adrenergic receptors. This produces central nervous system (CNS) stimulation that may oppose the sedative effects of ketotifen, a histamine H1-receptor antagonist with sedative properties. Consequently, coadministration may result in reduced efficacy of ketotifen for sedation or sleep induction, potentially compromising its therapeutic benefit in conditions requiring CNS depression (e.g., allergic rhinitis, urticaria)."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PBZ vs ACUVUE THERAVISION WITH KETOTIFEN, answered by our medical review team.
PBZ is a Antihistamine that works by PBZ (phenylbutazone) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis. It also has uricosuric effects.. ACUVUE THERAVISION WITH KETOTIFEN is a Antihistamine / Mast Cell Stabilizer that works by Ketotifen is a selective histamine H1-receptor antagonist and mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and leukotrienes from mast cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PBZ and ACUVUE THERAVISION WITH KETOTIFEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PBZ is: 25-50 mg orally every 4-6 hours as needed; not to exceed 300 mg/day. For severe allergies: 25 mg intramuscularly or intravenously every 4-6 hours.. The standard adult dose of ACUVUE THERAVISION WITH KETOTIFEN is: One drop in each affected eye twice daily (approximately 8 hours apart) as needed. The lens should be removed prior to instillation and can be reinserted after at least 10 minutes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PBZ and ACUVUE THERAVISION WITH KETOTIFEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PBZ is classified as Category C. PBZ (Piroxicam) is a nonsteroidal anti-inflammatory drug (NSAID). First trimester: Avoid use; associated with increased risk of miscarriage and congenital malformations (e.g., card. ACUVUE THERAVISION WITH KETOTIFEN is classified as Category A/B. Ketotifen ophthalmic solution has minimal systemic absorption (approximately 0.1% of administered dose). No adequate well-controlled studies in pregnant women. Animal studies showe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.